| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
| Targets |
As an amino acid derivative, Selenocystamine dihydrochloride does not have a defined primary drug target in the context of therapeutic development. However, as a selenium-containing compound, it may be used in research to study selenium biochemistry, redox biology, and antioxidant defense mechanisms. Selenium is an essential trace element that plays critical roles in antioxidant enzymes such as glutathione peroxidases and thioredoxin reductases. The diselenide bond in selenocystamine can participate in redox reactions, making it useful for studying oxidative stress and thiol-disulfide exchange reactions. The compound can also serve as a precursor for the synthesis of selenocysteine-containing peptides and other selenium-containing bioactive compounds.
|
|---|---|
| ln Vitro |
In vitro studies on selenium-containing amino acid derivatives have demonstrated their capacity to modulate redox balance, influence antioxidant enzyme activity, and affect cellular signaling pathways. Selenocystamine dihydrochloride can induce the aggregation of amphiphilic p-sulfonatocalixarene to form supramolecular nanoparticles, suggesting potential applications in drug delivery and nanomedicine. As a selenocysteine derivative, this compound may be used in cell-based assays to investigate selenium metabolism, redox signaling, and the effects of selenium supplementation on cellular function. The compound can also be utilized in studies examining the role of selenium in cancer prevention and treatment.
|
| ln Vivo |
In vivo studies on selenium-containing compounds have shown that selenium plays critical roles in antioxidant defense, thyroid hormone metabolism, and immune function. Selenocystamine dihydrochloride may be administered in animal studies to evaluate the effects of selenium supplementation or to study the pharmacokinetics and bioavailability of selenium-containing compounds. However, specific in vivo pharmacological data for this exact compound remains limited, as it is primarily supplied as a research chemical for synthesis and supramolecular chemistry applications. The compound's diselenide bond may be reduced in vivo to release selenocysteine or other selenium metabolites.
|
| Enzyme Assay |
Non-cell-based enzyme or receptor binding assays for this compound typically involve redox chemistry studies using purified enzymes such as thioredoxin reductase or glutathione peroxidase. Standard protocols include incubating varying concentrations of the test compound with the enzyme source in appropriate buffer systems, followed by measurement of enzymatic activity using spectrophotometric or fluorometric detection methods. The diselenide bond can participate in thiol-diselenide exchange reactions with thiol-containing compounds, which can be monitored using Ellman's reagent or other thiol detection methods. For supramolecular chemistry applications, the compound's ability to induce nanoparticle formation can be studied using dynamic light scattering (DLS) or transmission electron microscopy (TEM).
|
| Cell Assay |
Cell-based assays for this selenocysteine derivative typically utilize mammalian cell lines to evaluate compound uptake, cytotoxicity, and effects on cellular redox status. Standard protocols involve culturing cells in appropriate media at 37°C in 5% CO₂, followed by treatment with varying concentrations of the compound (typically 0.1-100 μM) for 24-72 hours. Cell viability is assessed using MTT or CCK-8 assays. The compound's effects on cellular glutathione levels and oxidative stress markers can be measured using fluorometric or colorimetric assays. For nanoparticle formation studies, cells may be treated with selenocystamine-induced nanoparticles to evaluate uptake and biological effects. All experiments should include appropriate vehicle controls and replicate measurements.
|
| Animal Protocol |
In vivo animal studies for selenium-containing compounds typically involve administration via oral gavage, intraperitoneal injection, or intravenous injection in rodent models (mice or rats). Standard protocols include dosing at ranges of 1-10 mg/kg body weight (selenium compounds often have narrow therapeutic windows), with observations over 1-14 days depending on the study objectives. For studies evaluating the effects of selenium supplementation, animals may be administered the compound and monitored for changes in antioxidant enzyme activity, immune function, or thyroid hormone levels. Pharmacodynamic assessments may include blood sampling for selenium analysis, tissue collection for histopathological examination, and monitoring of body weight and general health parameters. All animal studies must comply with institutional ethical guidelines.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties for this selenium-containing compound can be inferred from structurally related selenium compounds. As a small molecule (molecular weight 318.99 g/mol), it is expected to be absorbed and distributed throughout body compartments. The diselenide bond is likely to be reduced in vivo to release selenocysteine or other selenium metabolites that can be incorporated into selenoproteins. The compound shows moderate solubility in DMSO (100 mg/mL) and can be formulated for in vitro studies. For in vivo administration, formulations using 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline may be employed. The compound should be stored as powder at -20°C for long-term preservation, protected from moisture. Definitive PK parameters require formal studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for this specific compound are limited as it is supplied for research use only. Selenium compounds can have narrow therapeutic windows, with both deficiency and excess causing adverse effects. Appropriate safety precautions should be observed during handling, including the use of personal protective equipment and work in well-ventilated areas. The compound may cause skin and eye irritation upon contact. Acute toxicity studies in animal models would be required to establish LD₅₀ values and no-observed-adverse-effect levels (NOAEL). For in vitro cytotoxicity assessment, the compound can be tested in mammalian cell lines using standard MTT or LDH release assays. The compound's redox activity may contribute to both beneficial antioxidant effects and potential pro-oxidant toxicity at high concentrations.
|
| Additional Infomation |
Selenocystamine dihydrochloride is a selenium-containing amino acid derivative featuring a diselenide bond, which is the selenium analogue of cystamine. Selenium is an essential trace element that plays critical roles in antioxidant enzymes such as glutathione peroxidases and thioredoxin reductases. This compound can be used in the synthesis of other active compounds and can induce the aggregation of amphiphilic p-sulfonatocalixarene to form supramolecular nanoparticles, suggesting potential applications in drug delivery and nanomedicine. The diselenide bond allows the compound to participate in redox reactions, making it useful for studying oxidative stress and thiol-disulfide exchange. It is not an approved drug and has not undergone clinical trials; it is strictly for research purposes only.
|
| Molecular Formula |
C4H14CL2N2SE2
|
|---|---|
| Molecular Weight |
318.99
|
| Exact Mass |
319.886
|
| CAS # |
3542-13-0
|
| PubChem CID |
15565403
|
| Appearance |
Light brown to orange solid powder
|
| Boiling Point |
327.9ºC at 760mmHg
|
| Flash Point |
152.1ºC
|
| LogP |
2.068
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
10
|
| Complexity |
37
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Se](C([H])([H])C([H])([H])N([H])[H])[Se]C([H])([H])C([H])([H])N([H])[H].Cl[H].Cl[H]
|
| InChi Key |
LACKHEAUUXZNBU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C4H12N2Se2.2ClH/c5-1-3-7-8-4-2-6;;/h1-6H2;2*1H
|
| Chemical Name |
2-(2-aminoethyldiselanyl)ethanamine;dihydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (313.49 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.84 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.84 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.84 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1349 mL | 15.6745 mL | 31.3489 mL | |
| 5 mM | 0.6270 mL | 3.1349 mL | 6.2698 mL | |
| 10 mM | 0.3135 mL | 1.5674 mL | 3.1349 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
